Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple SclerosisGlobeNewsWire • 03/30/21
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021GlobeNewsWire • 03/10/21
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/23/21
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental MedicinesGlobeNewsWire • 02/22/21
The $12 Billion Market That Has Biotech Stocks Hijacking The Immune SystemInvestors Business Daily • 02/12/21
Genmab, Seagen File US Application For Tisotumab Vedotin In Cervical Cancer SettingBenzinga • 02/11/21
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 02/10/21
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical CancerGlobeNewsWire • 02/10/21
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical CancerGlobeNewsWire • 01/04/21
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung CancerGlobeNewsWire • 12/03/20
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell LymphomaGlobeNewsWire • 11/05/20
Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosisGlobeNewsWire • 11/05/20
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20